Аnti-müllerian hormone as a diagnostic marker of polycystic ovary syndrome

Grodnitskaia E.É.

Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia, Moskva

Shcherbatiuk Iu.V.

GBUZ "Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia goroda Moskvy"

Bendusov I.A.

GBUZ "Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia goroda Moskvy"

Kurtser M.A.

Tsentr planirovaniia sem'i i reproduktsii DZ Moskvy

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Аnti-müllerian hormone as a diagnostic marker of polycystic ovary syndrome

Authors:

Grodnitskaia E.É., Shcherbatiuk Iu.V., Bendusov I.A., Kurtser M.A., Melnichenko G.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2013;(6): 27‑30

Downloaded: 178

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Grodnitskaia EÉ, Shcherbatiuk IuV, Bendusov IA, Kurtser MA, Melnichenko GA. Аnti-müllerian hormone as a diagnostic marker of polycystic ovary syndrome. Russian Journal of Human Reproduction. 2013;(6):27‑30. (In Russ.)

Close metadata

Recommended articles:

Perspective directions in the treatment of polycystic ovary syndrome (literature review). Russian Journal of Human Reproduction. 2024;(3):94-104

Features of the course of induced pregnancy during the transfer of a thawed embryo in women with polycystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(1):54-62

Gonadotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36

Serum Аnti-Müllerian hormone (AMH) in patients with polycystic ovary syndrome (PCOS) correlated with the severity of symptoms. It is an accurate marker of the antral follicle number and offers a good diagnostic potency. A cross-sectional study was performed in 62 women diagnosed with PCOS according to the ESHRE/ASRM criteria and in 67 healthy control subjects matched by age and body mass index. Serum AMH levels were significantly higher in women with PCOS. ROC curve analysis showed a cutoff point for AMH of 4.96 ng/mL (sensitivity 72.1%, specificity 90.2%) for diagnosis of PCOS. AMH has a high specificity and sensitivity as a diagnostic marker for PCOS.

Keywords:

аnti-Müllerian hormone

diagnostic marker

polycystic ovary syndrome

Authors:

Grodnitskaia E.É.

Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia, Moskva

Shcherbatiuk Iu.V.

GBUZ "Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia goroda Moskvy"

Bendusov I.A.

GBUZ "Tsentr planirovaniia sem'i i reproduktsii Departamenta zdravookhraneniia goroda Moskvy"

Kurtser M.A.

Tsentr planirovaniia sem'i i reproduktsii DZ Moskvy

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

List of references:

Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., Witchel S.F. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metabol 2006; 91: 11: 4237-4245.
Bozdag G., Salman M.C., Mumusoglu S., Yapici Z., Gunalp S. Is ovarian volume estimation reliable when compared with true volume? Am J Obstet Gynecol 2012; 206: 1: 44:e1-e4.
Brett S., Bee N., Wallace W.H., Rajkhowa M., Kelsey T.W. Individual ovarian volumes obtained from 2-dimensional and 3-dimensional ultrasound lack precision. Reprod Biomed Online 2009; 18: 3: 348-351.
Cohen H.L., Tice H.M., Mandel F.S. Ovarian volumes measured by US: bigger than we think. Radiology 1990; 177: 189-192.
Dewailly D., Gronier H., Poncelet E., Robin G., Leroy M., Pigny P., Duhamel A., Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26: 11: 3123-3129.
Eilertsen T.B., Vanky E., Carlsen S.M. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012; 27: 8: 2494-2502.
Eldar-Geva T., Margalioth E.J., Gai M., Ben-Chetrit A., Algur N., Zylber- Haran E., Brooks B., Huerta M., Spitz I.M. Serum anti-Mullerianhormone levels during controlled ovarian hyperstimulation in women inpolycystic ovaries with and without hyperandrogenism. Human Reprod 2005; 20: 1814-1819.
Iliodromiti S., Kelsey T.W., Anderson R.A., Nelson S.M. Can anti-mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and metaanalysis of extracted data. J Clin Endocrinol Metabol 2013; 98: 8: 3332-3340.
La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82: 970-972.
Laven J.S.E., Mulders A.M., Visser J., Themmen A.P., de Jong F.H., Fauser B.C.J.M. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metabol 2004; 89: 318-323.
Lin Y.H., Chiu W.C., Wu C.H., Tzeng C.R., Hsu C.S., Hsu M.I. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96: 1: 230-235.
Lujan M.E., Chizen D.R., Pierson R.A. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can 2008; 30: 8: 671-679.
March W.A., Moore V.M., Willson K.J., Phillips D.I., Norman R.J., Davies M.J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 2: 544-551.
Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest 2010; 69: 4: 274-280.
Nardo L.G., Yates A.P., Roberts S.A., Pemberton P., Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obesesubfertile women with and without polycystic ovary syndrome. Hum Reprod 2009; 24: 11: 2917-2923.
Pellatt L., Hanna L., Brincat M., Galea R., Brain H., Whitehead S., Mason H.D. Granulosa cell production of anti-Mullerian hormone (AMH) is increased in the polycystic ovary. J Clin Endocrinol Metabol 2007; 90: 240-245.
Pellatt L., Rice S., Mason H.D. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010; 139: 5: 825-833.
Pigny P., Jonard S., Robert Y., Dewailly D. Serum anti-Muüllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metabol 2006; 91: 941-945.
Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metabol 2009; 296: E238-E243.
Rosendahl M., Ernst E., Rasmussen P.E., Andersen C.Y. True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement. Fertil Steril 2010; 93: 3: 995-998.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
Woo H.Y., Kim K.H., Rhee E.J., Park H., Lee M.K. Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocrinol J 2012; 59: 9: 781-790.

Close metadata